Phio Pharmaceuticals Corp. announced on June 25, 2025, that its Safety Monitoring Committee (SMC) recommended dose escalation in the Phase 1b clinical trial for PH-762. This positive recommendation allows the study to advance to the fifth dose escalation cohort, which is expected to be the final cohort in the trial.
The decision was based on the supportive safety profile observed in the fourth cohort, demonstrating continued tolerability of PH-762 at escalating doses. The Phase 1b clinical trial is designed to evaluate the safety and tolerability of intratumoral (IT) PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.
Mary Spellman, MD, Phio's acting Chief Medical Officer, noted that PH-762 continues to demonstrate a supportive safety profile as it progresses through the dose escalation. This advancement is a critical step towards completing the dose-finding phase of the study and moving closer to identifying an optimal therapeutic dose for future clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.